We want to start this article to remind everybody about the importance of May 8th. It is the international designated day for Ovarian Cancer because it is one of the most lethal female cancers. Noteworthy, this term refers to a wide number of different cancer types mostly based on the type of cell they come from. The most common is epithelial ovarian cancer, which usually originates on the surface of the ovaries, but it can also arise in the fallopian tubes or in the primary peritoneal cavity. And to a much lower extend, we can also find germ cell ovarian cancer, stromal cells ovarian cancer and small cell carcinoma of the ovary. Unfortunately, despite of its origins, female checks up are the only option to find this cancer at the early stages because there are no current  reliable screening tests making it one of those “silent” cancers that only shows up once it has already spread and it is too late.

Currently, the five-year survival rates vary between 36% and 46% and sadly, the expectations are not good; the number of newly diagnosed and dying women will only continue to increase in the next decades, in some cases up to 50%. These devastating numbers are based on the facts that the standard treatment of care is chemotherapy and/or surgery if possible.

Let´s hope that recent clinical trials testing PARP inhibitors such as olaparib (SOLO-1), or immunotherapy combining checkpoints inhibitors like ipilimumab and nivolumab, will help to improve the expectations.